Key Insights

Highlights

Success Rate

79% trial completion

Published Results

42 trials with published results (19%)

Research Maturity

108 completed trials (49% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

12.8%

28 terminated out of 219 trials

Success Rate

79.4%

-7.2% vs benchmark

Late-Stage Pipeline

4%

9 trials in Phase 3/4

Results Transparency

39%

42 of 108 completed with results

Key Signals

42 with results79% success28 terminated

Data Visualizations

Phase Distribution

169Total
Not Applicable (85)
Early P 1 (9)
P 1 (33)
P 2 (33)
P 3 (9)

Trial Status

Completed108
Recruiting43
Terminated28
Unknown13
Active Not Recruiting12
Withdrawn9

Trial Success Rate

79.4%

Benchmark: 86.6%

Based on 108 completed trials

Clinical Trials (219)

Showing 20 of 20 trials
NCT02243592Active Not RecruitingPrimary

Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment

NCT05103358Phase 2Completed

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

NCT07630974Phase 1RecruitingPrimary

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

NCT07600749Phase 1RecruitingPrimary

Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

NCT06979596Phase 2RecruitingPrimary

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

NCT03471364Early Phase 1CompletedPrimary

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

NCT06941272Phase 1RecruitingPrimary

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

NCT07700758Phase 2Not Yet RecruitingPrimary

A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

NCT07247110Phase 1RecruitingPrimary

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

NCT03857620Not ApplicableCompletedPrimary

Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer

NCT06818643Phase 1Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT02479698Phase 2Recruiting

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

NCT07252739Phase 2RecruitingPrimary

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

NCT02402244Recruiting

Project: Every Child for Younger Patients With Cancer

NCT07785609Phase 2Not Yet Recruiting

A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

NCT02699697Not ApplicableCompletedPrimary

Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis

NCT04410302Recruiting

Patient-Derived Xenografts to Reduce Cancer Health Disparities

NCT07440290Phase 2Recruiting

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

NCT03696030Phase 1Active Not RecruitingPrimary

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

NCT03741673Phase 3Active Not RecruitingPrimary

Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases

Scroll to load more

Research Network

Activity Timeline